Golimumab reduces sleep disturbance in patients with active ankylosing spondylitis

Results from a randomized, placebo-controlled trial

Atulya (Atul) Deodhar, Jürgen Braun, Robert D. Inman, Michael Mack, Shreekant Parasuraman, Jacqueline Buchanan, Benjamin Hsu, Tim Gathany, Désirée Van Der Heijde

Research output: Contribution to journalArticle

35 Citations (Scopus)

Abstract

Objective. To evaluate the effect of golimumab on sleep disturbance in patients with active ankylosing spondylitis (AS). Methods. Golimumab was studied in a multicenter, randomized, placebo-controlled study (GO-RAISE). At baseline, 356 patients were randomly assigned in a 1.8:1.8:1 ratio to subcutaneous golimumab 50 mg, 100 mg, or placebo every 4 weeks. Sleep disturbance was assessed using the Jenkins Sleep Evaluation Questionnaire (JSEQ), which was administered at baseline, week 14, and week 24. Treatment effect was evaluated using analysis of variance on the van der Waerden normal scores. Results. Median JSEQ scores at baseline were 9.0 in the placebo group, 10.0 in the 50-mg group, and 11.0 in the 100-mg group, indicating moderate to severe sleep disturbance. Patients who received golimumab showed significantly greater median improvement from baseline in JSEQ scores compared with placebo at week 14 (-3.0 versus 0.0; P <0.001) and week 24 (-3.0 versus -1.0; P <0.001). Changes from baseline in JSEQ scores significantly correlated with changes from baseline in Short Form 36 summary scores, Bath AS Functional Index scores, total back pain, night back pain, and Bath AS Disease Activity Index scores. Multiple regression analyses indicated that improvement in the night back pain score was the most consistent predictor of change in JSEQ score or reduction in sleep disturbance. Conclusion. Patients with active AS showed significant sleep disturbance at baseline due to underlying pain associated with AS. Treatment with subcutaneous golimumab every 4 weeks significantly reduced sleep disturbance and improved health-related quality of life.

Original languageEnglish (US)
Pages (from-to)1266-1271
Number of pages6
JournalArthritis Care and Research
Volume62
Issue number9
DOIs
StatePublished - 2010

Fingerprint

Ankylosing Spondylitis
Sleep
Randomized Controlled Trials
Placebos
Back Pain
Baths
golimumab
Analysis of Variance
Regression Analysis
Quality of Life
Surveys and Questionnaires
Pain

ASJC Scopus subject areas

  • Rheumatology
  • Medicine(all)

Cite this

Golimumab reduces sleep disturbance in patients with active ankylosing spondylitis : Results from a randomized, placebo-controlled trial. / Deodhar, Atulya (Atul); Braun, Jürgen; Inman, Robert D.; Mack, Michael; Parasuraman, Shreekant; Buchanan, Jacqueline; Hsu, Benjamin; Gathany, Tim; Van Der Heijde, Désirée.

In: Arthritis Care and Research, Vol. 62, No. 9, 2010, p. 1266-1271.

Research output: Contribution to journalArticle

Deodhar, AA, Braun, J, Inman, RD, Mack, M, Parasuraman, S, Buchanan, J, Hsu, B, Gathany, T & Van Der Heijde, D 2010, 'Golimumab reduces sleep disturbance in patients with active ankylosing spondylitis: Results from a randomized, placebo-controlled trial', Arthritis Care and Research, vol. 62, no. 9, pp. 1266-1271. https://doi.org/10.1002/acr.20233
Deodhar, Atulya (Atul) ; Braun, Jürgen ; Inman, Robert D. ; Mack, Michael ; Parasuraman, Shreekant ; Buchanan, Jacqueline ; Hsu, Benjamin ; Gathany, Tim ; Van Der Heijde, Désirée. / Golimumab reduces sleep disturbance in patients with active ankylosing spondylitis : Results from a randomized, placebo-controlled trial. In: Arthritis Care and Research. 2010 ; Vol. 62, No. 9. pp. 1266-1271.
@article{7d30101b62c94a109723fdb1cecfc986,
title = "Golimumab reduces sleep disturbance in patients with active ankylosing spondylitis: Results from a randomized, placebo-controlled trial",
abstract = "Objective. To evaluate the effect of golimumab on sleep disturbance in patients with active ankylosing spondylitis (AS). Methods. Golimumab was studied in a multicenter, randomized, placebo-controlled study (GO-RAISE). At baseline, 356 patients were randomly assigned in a 1.8:1.8:1 ratio to subcutaneous golimumab 50 mg, 100 mg, or placebo every 4 weeks. Sleep disturbance was assessed using the Jenkins Sleep Evaluation Questionnaire (JSEQ), which was administered at baseline, week 14, and week 24. Treatment effect was evaluated using analysis of variance on the van der Waerden normal scores. Results. Median JSEQ scores at baseline were 9.0 in the placebo group, 10.0 in the 50-mg group, and 11.0 in the 100-mg group, indicating moderate to severe sleep disturbance. Patients who received golimumab showed significantly greater median improvement from baseline in JSEQ scores compared with placebo at week 14 (-3.0 versus 0.0; P <0.001) and week 24 (-3.0 versus -1.0; P <0.001). Changes from baseline in JSEQ scores significantly correlated with changes from baseline in Short Form 36 summary scores, Bath AS Functional Index scores, total back pain, night back pain, and Bath AS Disease Activity Index scores. Multiple regression analyses indicated that improvement in the night back pain score was the most consistent predictor of change in JSEQ score or reduction in sleep disturbance. Conclusion. Patients with active AS showed significant sleep disturbance at baseline due to underlying pain associated with AS. Treatment with subcutaneous golimumab every 4 weeks significantly reduced sleep disturbance and improved health-related quality of life.",
author = "Deodhar, {Atulya (Atul)} and J{\"u}rgen Braun and Inman, {Robert D.} and Michael Mack and Shreekant Parasuraman and Jacqueline Buchanan and Benjamin Hsu and Tim Gathany and {Van Der Heijde}, D{\'e}sir{\'e}e",
year = "2010",
doi = "10.1002/acr.20233",
language = "English (US)",
volume = "62",
pages = "1266--1271",
journal = "Arthritis and Rheumatology",
issn = "2326-5191",
publisher = "John Wiley and Sons Ltd",
number = "9",

}

TY - JOUR

T1 - Golimumab reduces sleep disturbance in patients with active ankylosing spondylitis

T2 - Results from a randomized, placebo-controlled trial

AU - Deodhar, Atulya (Atul)

AU - Braun, Jürgen

AU - Inman, Robert D.

AU - Mack, Michael

AU - Parasuraman, Shreekant

AU - Buchanan, Jacqueline

AU - Hsu, Benjamin

AU - Gathany, Tim

AU - Van Der Heijde, Désirée

PY - 2010

Y1 - 2010

N2 - Objective. To evaluate the effect of golimumab on sleep disturbance in patients with active ankylosing spondylitis (AS). Methods. Golimumab was studied in a multicenter, randomized, placebo-controlled study (GO-RAISE). At baseline, 356 patients were randomly assigned in a 1.8:1.8:1 ratio to subcutaneous golimumab 50 mg, 100 mg, or placebo every 4 weeks. Sleep disturbance was assessed using the Jenkins Sleep Evaluation Questionnaire (JSEQ), which was administered at baseline, week 14, and week 24. Treatment effect was evaluated using analysis of variance on the van der Waerden normal scores. Results. Median JSEQ scores at baseline were 9.0 in the placebo group, 10.0 in the 50-mg group, and 11.0 in the 100-mg group, indicating moderate to severe sleep disturbance. Patients who received golimumab showed significantly greater median improvement from baseline in JSEQ scores compared with placebo at week 14 (-3.0 versus 0.0; P <0.001) and week 24 (-3.0 versus -1.0; P <0.001). Changes from baseline in JSEQ scores significantly correlated with changes from baseline in Short Form 36 summary scores, Bath AS Functional Index scores, total back pain, night back pain, and Bath AS Disease Activity Index scores. Multiple regression analyses indicated that improvement in the night back pain score was the most consistent predictor of change in JSEQ score or reduction in sleep disturbance. Conclusion. Patients with active AS showed significant sleep disturbance at baseline due to underlying pain associated with AS. Treatment with subcutaneous golimumab every 4 weeks significantly reduced sleep disturbance and improved health-related quality of life.

AB - Objective. To evaluate the effect of golimumab on sleep disturbance in patients with active ankylosing spondylitis (AS). Methods. Golimumab was studied in a multicenter, randomized, placebo-controlled study (GO-RAISE). At baseline, 356 patients were randomly assigned in a 1.8:1.8:1 ratio to subcutaneous golimumab 50 mg, 100 mg, or placebo every 4 weeks. Sleep disturbance was assessed using the Jenkins Sleep Evaluation Questionnaire (JSEQ), which was administered at baseline, week 14, and week 24. Treatment effect was evaluated using analysis of variance on the van der Waerden normal scores. Results. Median JSEQ scores at baseline were 9.0 in the placebo group, 10.0 in the 50-mg group, and 11.0 in the 100-mg group, indicating moderate to severe sleep disturbance. Patients who received golimumab showed significantly greater median improvement from baseline in JSEQ scores compared with placebo at week 14 (-3.0 versus 0.0; P <0.001) and week 24 (-3.0 versus -1.0; P <0.001). Changes from baseline in JSEQ scores significantly correlated with changes from baseline in Short Form 36 summary scores, Bath AS Functional Index scores, total back pain, night back pain, and Bath AS Disease Activity Index scores. Multiple regression analyses indicated that improvement in the night back pain score was the most consistent predictor of change in JSEQ score or reduction in sleep disturbance. Conclusion. Patients with active AS showed significant sleep disturbance at baseline due to underlying pain associated with AS. Treatment with subcutaneous golimumab every 4 weeks significantly reduced sleep disturbance and improved health-related quality of life.

UR - http://www.scopus.com/inward/record.url?scp=77956396153&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77956396153&partnerID=8YFLogxK

U2 - 10.1002/acr.20233

DO - 10.1002/acr.20233

M3 - Article

VL - 62

SP - 1266

EP - 1271

JO - Arthritis and Rheumatology

JF - Arthritis and Rheumatology

SN - 2326-5191

IS - 9

ER -